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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S135real-time PCR. The phosphorylation of ERK was measured by ELISA. MKP-1
expression was measured by real-time PCR and western blotting.
Results: IL-6+sIL-6R, IL-1b and TNF-a inducedMMP-3 andADAMTS-4mRNA
in human articular chondrocytes in a concentration-dependent manner.
Moreover, all three cytokinespromoted thephosphorylation of ERK,whereas
the total amount of ERK did not change. Both HA and ERK inhibitor
completely inhibitedMMP-3 andADAMTS-4mRNA inductionby IL-6+sIL-6R
or IL-1b, but both did not inhibit MMP-3 and ADAMTS-4mRNA induction by
TNF-a. Both HA and ERK inhibitor completely suppressed the phosphoryla-
tion of ERK induced by all cytokines in human articular chondrocytes.
To further analyze the inhibitory action of HA on ERK signal pathways
induced by IL-6+sIL-6R and IL-1b, we tested whether HA could induce
MKP-1, a negative regulator of ERK. HA treatment induced the expression
of MKP-1 mRNA and its protein in human articular chondrocytes.
To determine the involvement of MKP-1 in HA-induced suppression of
MMP-3 and ADAMTS-4 expressions induced by IL-6+sIL-6R and IL-1b, we
examined whether MKP-1 inhibitor could block the effect of HA. MKP-1
inhibitor clearly reversed the suppressive effect of HA on MMP-3 and
ADAMTS-4 expressions induced by IL-6+sIL-6R and IL-1b.
Conclusions: Our study clearly demonstrates that ERK involves in the
induction of MMP-3 and ADAMTS-4 by IL-6+sIL-6R and IL-1b, but not by
TNF-a. HA suppresses the induction of MMP-3 and ADAMTS-4 via the
induction of MKP-1, a negative regulator of ERK.
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RECOMBINANT HUMAN FIBROBLAST GROWTH FACTOR-18 (RHFG18)
PROMOTES BOVINE ARTICULAR CHONDROCYTE PROLIFERATION AND
CARTILAGE MATRIX PRODUCTION IN VITRO.
A. Gigout, D. Werkmann, S. Lindemann, K. Kleinschmidt,
H. Guehring. Merck-Serono, Darmstadt, GERMANY
Purpose: An important goal in the treatment of patients with osteoar-
thritis and cartilage injury is to restore the articular surface of degraded or
injured cartilage. Regeneration could be achieved by anabolic compounds
stimulating extracellular matrix (ECM) molecule production and recellu-
larization, thereby compensating for the matrix and cell loss occurring in
OA cartilage. The present work sought to evaluate the ability of recombi-
nant human ﬁbroblast growth factor-18 (rhFGF18) to exhibit such prop-
erties in various in vitro and ex vivo systems.
Methods: Primary bovine articular chondrocytes were tested for expres-
sion of ﬁbroblast growth factor receptor 3 (FGFR3, the main receptor for
rhFGF18 signaling in cartilage) at the mRNA and protein level by quanti-
tative polymerase chain reaction (qPCR) and Western Blot, respectively. A
dose-response curve (0.1-10 000 ng/mL rhFGF18) was realized in mono-
layer to determine the best dosage. Next, 3D cultures with 10 and 100 ng/
mL rhFGF18 were performed with rhFGF18 applied for 4 weeks (4w), or for
1 week followed by 3 weeks without rhFGF18 (1w). Cell proliferation was
evaluated in monolayer using a cell counter. ECM production and the
chondrocytic phenotype were investigated for both monolayer and 3D
cultures by qPCR for collagen I, II, X, aggrecan and Sox9. Glycosamino-
glycan (GAG) content of the 3D constructs was also evaluated with the
dimethylmethylene blue assay after proteinase K digestion. Finally, the
impact of rhFGF18 (100 ng/mL) on proliferation in bovine cartilage
explants was assessed. For this purpose, cell counting using automated
image analysis was done after 41 days of culture with/without rhFGF18. In
a second trial, cell proliferation was quantiﬁed using proliferating cell
nuclear antigen (PCNA) staining in histological sections in bovine cartilage
explants after 0, 2, 4, 6 weeks' rhFGF18 administration.
Results: At both the protein and mRNA levels, primary bovine articular
chondrocytes expressed FGFR3. In monolayer cell culture they responded
to rhFGF18 with a dose-dependent increase in proliferation (1.9 fold at 10
ng/mL) and a dose-dependent decrease of collagen type I expression (64
fold at 100 ng/mL). In 3D culture (see Figure), short exposure to rhFGF18
100 ng/mL (1w) triggered GAG production (1.5 fold) and collagen type II
expression (3.2 fold), while collagen type I expression was decreased (2.3
fold). Chondrocyte proliferation was also stimulated in bovine cartilage
explants by 100 ng/mL rhFGF18, demonstrating its ability to reach the cells
in cartilage. The maximum effect of rhFGF18 on explants was observedafter 4 weeks in culture (11.25% PCNA positive cells with rhFGF18 treat-
ment compared to 4.88% PCNA positive cells without rhFGF18).Figure: GAG content and collagen (Col.) types I and II gene expression in 3D
constructs cultured in absence (CTR, control) or presence of rhFGF18 (100
ng/mL) over a 4-week culture period (4w) or for the ﬁrst week (1w) only.
Conclusions: Taken together these results suggest that rhFGF18 can efﬁ-
ciently penetrate cartilage, and stimulate chondrocyte proliferation and
cartilage ECM production. This is consistent with previous in vitro studies
and further strengthens the rationale for the current clinical investigation
of rhFGF18 as an anabolic disease modifying osteoarthritis drug (DMOAD).261
A UNIQUE TOOL TO SELECTIVELY DETECT THE CHONDROGENIC IIB
FORM OF HUMAN PROCOLLAGEN II PROTEIN.
E. Aubert-Foucher 1, M. Pasdeloup 1, N. Mayer 1, A. Pagnon 2,
D. Hartmann 3, F. Mallein-Gerin 1. 1Université Lyon 1, Univ Lyon, CNRS,
FRE 3310 - Dysfonctionnement de l'Homéostasie Tissulaire et Ingénierie
Thérapeutique, IBCP, F69367 Lyon, France; 2Novotec, 13-15 rue Jacques
Monod, F69007 Lyon, France; 3UCBL 1/ISPB, Faculté de Pharmacie, UMR
CNRS 5510/MATEIS, Equipe I2B -"Interactions Biologiques et Biomatériaux",
8 avenue Rockefeller, F69373 Lyon, Cedex 08, France
Purpose: Type II collagen, the major ﬁbrillar collagen of cartilage, is
synthesized in precursor forms (procollagens) containing NH2- and COOH-
terminal propeptides. Three splice variants are thought to be translated to
produce procollagen II isoforms (IIA/IID and IIB) that differ in their ami-
nopropeptide parts. The IIA and IID are transient embryonic isoforms
which include an additional cysteine rich domain implicated in the regu-
lation of TGF-b superfamily signalling. The IIA and IID transcripts are co-
expressed during chondrogenesis then decline and the IIB isoform is the
only one expressed and synthesized in mature fully differentiated chon-
drocytes. Besides, procollagen IIA can be re-expressed by dedifferentiating
chondrocytes and in osteoarthritic cartilage. Therefore, it is an important
point to determine which isoform(s) is (are) synthesized in vivo in normal
and pathological situations and in vitro, to complete the phenotypic
characterization of collagen II protein producing cells. Antibodies directed
against the cysteine rich extradomain of procollagen IIA are already
available and our goal in this study was to obtain and validate for the ﬁrst
time antibodies detecting only the chondrogenic IIB form of procollagen II.
Methods:Wedesigned a triple peptide anti-peptide strategy to produce, to
titer by ELISA and to afﬁnity-purify rabbit polyclonal antibodies to human
procollagen IIB. Human knee chondrocytes and the Saos-2 human osteo-
blastic cell line were cultured in various conditions to prepare cell extracts
and media for the analysis of ﬁbrillar procollagens synthesized and
recognized by our antibodies to procollagen IIB by Western-blotting (WB).
Results: The antibodies to procollagen IIB (now referred to as anti-pNIIB52
antibodies) show a strong reactivity in WB with procollagen II and with
pN-collagen IIB (the form lacking the COOH-terminal propeptide but still
containing the NH2-terminal one) when compared to antibodies directed
against the triple-helical part of type II collagen. These forms are the only
bands revealed in the cell layer of chondrocytes cultured for 36 hours after
